Lipocine Inc (LPCN)
4.635
-0.10
(-2.01%)
USD |
NASDAQ |
Apr 30, 16:00
4.63
0.00 (0.00%)
After-Hours: 20:00
Lipocine Free Cash Flow: -11.88M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -11.88M |
| September 30, 2023 | -11.78M |
| June 30, 2023 | -12.38M |
| March 31, 2023 | -12.12M |
| December 31, 2022 | -12.10M |
| September 30, 2022 | -1.172M |
| June 30, 2022 | -4.955M |
| March 31, 2022 | -4.262M |
| December 31, 2021 | -4.411M |
| September 30, 2021 | -17.09M |
| June 30, 2021 | -14.27M |
| March 31, 2021 | -15.99M |
| December 31, 2020 | -15.30M |
| September 30, 2020 | -14.93M |
| June 30, 2020 | -13.56M |
| March 31, 2020 | -12.04M |
| December 31, 2019 | -11.67M |
| September 30, 2019 | -10.59M |
| June 30, 2019 | -11.15M |
| March 31, 2019 | -11.34M |
| December 31, 2018 | -12.08M |
| September 30, 2018 | -14.14M |
| June 30, 2018 | -15.35M |
| Date | Value |
|---|---|
| March 31, 2018 | -17.31M |
| December 31, 2017 | -16.70M |
| September 30, 2017 | -14.95M |
| June 30, 2017 | -14.44M |
| March 31, 2017 | -14.93M |
| December 31, 2016 | -18.34M |
| September 30, 2016 | -18.71M |
| June 30, 2016 | -20.23M |
| March 31, 2016 | -18.89M |
| December 31, 2015 | -15.38M |
| September 30, 2015 | -16.47M |
| June 30, 2015 | -13.40M |
| March 31, 2015 | -17.18M |
| December 31, 2014 | -17.36M |
| September 30, 2014 | -17.48M |
| June 30, 2014 | -19.45M |
| March 31, 2014 | -11.81M |
| December 31, 2013 | -8.590M |
| September 30, 2013 | -2.388M |
| June 30, 2013 | -0.0034M |
| March 31, 2013 | -0.0579M |
| December 31, 2012 | -0.0629M |
Free Cash Flow Range, Past 5 Years
-17.09M
Minimum
Sep 2021
-1.172M
Maximum
Sep 2022
-11.14M
Average
-12.04M
Median
Mar 2020
Free Cash Flow Benchmarks
| Alpine Immune Sciences Inc | -79.50M |
| Eliem Therapeutics Inc | -20.60M |
| NovaBay Pharmaceuticals Inc | -4.15M |
| Palatin Technologies Inc | -26.75M |
| iBio Inc | -18.89M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -2.022M |
| Cash from Investing (Quarterly) | 2.727M |
| Cash from Financing (Quarterly) | -0.0053M |
| Free Cash Flow Per Share (Quarterly) | -0.3821 |
| Free Cash Flow to Equity (Quarterly) | -2.032M |
| Free Cash Flow to Firm (Quarterly) | -2.032M |
| Free Cash Flow Yield | -48.75% |